---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-24-000025"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T10:58:58.041730+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# BioRestorative to present Phase 2 BRTX-100 data at ORS meeting, host webcast Feb 5

## Summary
- Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented at ORS 2024 Annual Meeting Feb 2-6 in Long Beach.
- Company will host a webcast conference call with slide presentation on Feb 5, 2024 at 8:30 a.m. ET to review the poster.
- No specific efficacy or safety results were disclosed in the press release.

## SEC filing metadata
- accession: 0001021771-24-000025
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000025/0001021771-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177124000025/bio8k2124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-24-000025
- JSON: https://secwatch.observer/filing/0001021771-24-000025.json
- Plain text: https://secwatch.observer/filing/0001021771-24-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.